[go: up one dir, main page]

PE20181919A1 - Amidas heterociclicas utiles como moduladores de proteinas - Google Patents

Amidas heterociclicas utiles como moduladores de proteinas

Info

Publication number
PE20181919A1
PE20181919A1 PE2018002003A PE2018002003A PE20181919A1 PE 20181919 A1 PE20181919 A1 PE 20181919A1 PE 2018002003 A PE2018002003 A PE 2018002003A PE 2018002003 A PE2018002003 A PE 2018002003A PE 20181919 A1 PE20181919 A1 PE 20181919A1
Authority
PE
Peru
Prior art keywords
useful
carboxamido
pyrazole
benzo
ethyl
Prior art date
Application number
PE2018002003A
Other languages
English (en)
Inventor
Adam Kenneth Charnley
Michael G Darcy
Jason W Dodson
Xiaoyang Dong
Terry V Hughes
Jianxing Kang
Lara Kathryn Leister
Yiqian Lian
Yue Li
John F Mehlmann
Neysa Nevins
Joshi M Ramanjulu
Joseph J Romano
Gren Z Wang
Guosen Ye
Daohua Zhang
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of PE20181919A1 publication Critical patent/PE20181919A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D498/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyridine Compounds (AREA)
  • Information Retrieval, Db Structures And Fs Structures Therefor (AREA)
  • Financial Or Insurance-Related Operations Such As Payment And Settlement (AREA)

Abstract

Se refiere a un compuesto que es (E)-1-(4-(5-carbamoil-2-(1-etil-3-metil-1H-pirazol-5-carboxamido)-1H-benzo[d]imidazol-1-il)but-2-en-1-il)-2-(-1-etil-3-metil-1H-pirazol-5-carboxamido)-1H-benzo[d]imidazol-1-il)but-2-en-1-il)-2-(1-etil-3-metil-1H-pirazol-5-carboxammido)-7-(3-morfolinopropoxi)-1H-benzo[d]imidazol-5-carboxamida. Tambien se refiere a una composicion farmaceutica y un metodo de tratamiento. Dichos compuestos son utiles como moduladores de la proteina transmembrana 173 (TMEM173) que tambien se conoce como STING (estimulador de los genes de interferon), y es util en el tratamiento de enfermedades alergicas, tales como el asma y la rinitis alergica, entre otros.
PE2018002003A 2016-04-07 2017-04-05 Amidas heterociclicas utiles como moduladores de proteinas PE20181919A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662319358P 2016-04-07 2016-04-07
US201762461301P 2017-02-21 2017-02-21
US201762461975P 2017-02-22 2017-02-22

Publications (1)

Publication Number Publication Date
PE20181919A1 true PE20181919A1 (es) 2018-12-11

Family

ID=58503675

Family Applications (3)

Application Number Title Priority Date Filing Date
PE2018002003A PE20181919A1 (es) 2016-04-07 2017-04-05 Amidas heterociclicas utiles como moduladores de proteinas
PE2018001834A PE20181884A1 (es) 2016-04-07 2017-04-05 Amidas heterociclicas utiles como moduladores de proteinas
PE2018002322A PE20181920A1 (es) 2016-04-07 2017-04-05 Amidas heterociclicas utiles como moduladores de proteinas

Family Applications After (2)

Application Number Title Priority Date Filing Date
PE2018001834A PE20181884A1 (es) 2016-04-07 2017-04-05 Amidas heterociclicas utiles como moduladores de proteinas
PE2018002322A PE20181920A1 (es) 2016-04-07 2017-04-05 Amidas heterociclicas utiles como moduladores de proteinas

Country Status (33)

Country Link
US (4) US10981901B1 (es)
EP (2) EP4032885A1 (es)
JP (4) JP6746712B2 (es)
KR (2) KR102527786B1 (es)
CN (3) CN109071514B (es)
AU (4) AU2017247798C1 (es)
CA (1) CA3019630A1 (es)
CL (3) CL2018002850A1 (es)
CO (1) CO2018010727A2 (es)
CR (2) CR20200044A (es)
DK (1) DK3440076T3 (es)
DO (3) DOP2018000217A (es)
ES (1) ES2921855T3 (es)
HR (1) HRP20220936T1 (es)
HU (1) HUE058932T2 (es)
IL (4) IL285702B (es)
JO (1) JOP20170083B1 (es)
LT (1) LT3440076T (es)
MX (3) MX387353B (es)
MY (1) MY189100A (es)
NZ (2) NZ745957A (es)
PE (3) PE20181919A1 (es)
PH (3) PH12018502151B1 (es)
PL (1) PL3440076T3 (es)
PT (1) PT3440076T (es)
RS (1) RS63462B1 (es)
SG (3) SG10201900629VA (es)
SI (1) SI3440076T1 (es)
SM (1) SMT202200339T1 (es)
TW (3) TWI868471B (es)
UA (1) UA123407C2 (es)
UY (1) UY37195A (es)
WO (1) WO2017175147A1 (es)

Families Citing this family (123)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202010609QA (en) 2015-08-13 2020-11-27 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
US11453697B1 (en) 2015-08-13 2022-09-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
ES2929628T3 (es) 2016-03-18 2022-11-30 Immune Sensor Llc Compuestos de dinucleótidos cíclicos y métodos de uso
PE20181919A1 (es) 2016-04-07 2018-12-11 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
MX386187B (es) 2016-10-04 2025-03-18 Merck Sharp & Dohme Llc Compuestos de benzo[b]tiofeno como agonistas de sting.
JOP20170192A1 (ar) 2016-12-01 2019-01-30 Takeda Pharmaceuticals Co داي نوكليوتيد حلقي
US11654197B2 (en) 2017-03-29 2023-05-23 Legochem Biosciences, Inc. Pyrrolobenzodiazepine dimer prodrug and ligand-linker conjugate compound of the same
TWI841526B (zh) 2017-04-13 2024-05-11 荷蘭商賽羅帕公司 抗-SIRPα 抗體
US11466047B2 (en) 2017-05-12 2022-10-11 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
EP3661499A4 (en) 2017-08-04 2021-04-21 Merck Sharp & Dohme Corp. COMBINATIONS OF PD-1 ANTAGONISTS AND STING BENZO AGONISTS [B
US11285131B2 (en) 2017-08-04 2022-03-29 Merck Sharp & Dohme Corp. Benzo[b]thiophene STING agonists for cancer treatment
JP7291130B2 (ja) * 2017-10-05 2023-06-14 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド インターフェロン遺伝子の刺激物質（ｓｔｉｎｇ）の調節物質
EP3691640A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Methods for administering sting agonists
EP3692033A1 (en) * 2017-10-05 2020-08-12 GlaxoSmithKline Intellectual Property Development Limited Modulators of stimulator of interferon genes (sting) useful in treating hiv
EP3707151B1 (en) 2017-11-10 2022-01-05 Takeda Pharmaceutical Company Limited Sting modulator compounds, and methods of making and using
KR102492187B1 (ko) 2017-12-20 2023-01-27 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. Sting 어댑터 단백질을 활성화하는 포스포네이트 결합을 가진 3'3' 사이클릭 다이뉴클레오티드
US11685761B2 (en) 2017-12-20 2023-06-27 Merck Sharp & Dohme Llc Cyclic di-nucleotide compounds as sting agonists
US11203610B2 (en) 2017-12-20 2021-12-21 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2′3′ cyclic dinucleotides with phosphonate bond activating the sting adaptor protein
CN110016021B (zh) * 2018-01-08 2021-05-07 成都先导药物开发股份有限公司 一种免疫调节剂
CN110016025B (zh) * 2018-01-08 2021-08-06 成都先导药物开发股份有限公司 一种免疫调节剂
JP2021513976A (ja) * 2018-02-16 2021-06-03 ユーシービー バイオファルマ エスアールエル 医薬活性を有する６，５複素二環式環誘導体
US11311528B2 (en) 2018-03-20 2022-04-26 Merck Sharp & Dohme Corp. Oxo-tetrahydro-isoquinoline carboxylic acids as STING inhibitors
US20210322327A1 (en) 2018-03-23 2021-10-21 Codiak Biosciences, Inc. Extracellular vesicles comprising sting-agonist
US11702430B2 (en) 2018-04-03 2023-07-18 Merck Sharp & Dohme Llc Aza-benzothiophene compounds as STING agonists
BR112020020085A8 (pt) 2018-04-03 2023-04-11 Merck Sharp & Dohme Composto, composição farmacêutica, e, métodos para induzir uma resposta imune, para induzir produção de interferons de tipo i dependentes de sting e para tratar um distúrbio de proliferação celular
TW202005654A (zh) 2018-04-06 2020-02-01 捷克科學院有機化學與生物化學研究所 ２，２，─環二核苷酸
TWI833744B (zh) 2018-04-06 2024-03-01 捷克科學院有機化學與生物化學研究所 3'3'-環二核苷酸
TWI818007B (zh) 2018-04-06 2023-10-11 捷克科學院有機化學與生物化學研究所 2'3'-環二核苷酸
US20190359645A1 (en) 2018-05-03 2019-11-28 Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. 2'3'-cyclic dinucleotides comprising carbocyclic nucleotide
GB201807924D0 (en) 2018-05-16 2018-06-27 Ctxt Pty Ltd Compounds
EP3802534B1 (en) * 2018-05-25 2022-07-13 Incyte Corporation Tricyclic heterocyclic compounds as sting activators
WO2020006432A1 (en) 2018-06-28 2020-01-02 Eternity Bioscience Inc. Fused tricyclic heterocycle compounds and therapeutic uses thereof
WO2020010451A1 (en) * 2018-07-10 2020-01-16 Trillium Therapeutics Inc. Heteroaromatic-fused imidazolyl amides, compositions and uses thereof as sting agonists
WO2020028566A1 (en) * 2018-07-31 2020-02-06 Incyte Corporation Heteroaryl amide compounds as sting activators
WO2020028565A1 (en) * 2018-07-31 2020-02-06 Incyte Corporation Tricyclic heteraryl compounds as sting activators
WO2020038387A1 (zh) 2018-08-24 2020-02-27 杭州阿诺生物医药科技有限公司 高活性sting蛋白激动剂
EP3841112A1 (en) 2018-08-24 2021-06-30 Codiak BioSciences, Inc. Extracellular vesicles targeting dendritic cells and uses thereof
CN111655682B (zh) * 2018-08-29 2024-05-31 杭州阿诺生物医药科技有限公司 一种高活性sting蛋白激动剂化合物
SMT202500141T1 (it) 2018-09-06 2025-05-12 Daiichi Sankyo Co Ltd Coniugati farmaco-anticorpo di derivati dinucleotidici ciclici
US11596692B1 (en) 2018-11-21 2023-03-07 Incyte Corporation PD-L1/STING conjugates and methods of use
WO2020115676A1 (en) 2018-12-06 2020-06-11 Glaxosmithkline Intellectual Property Development Limited Novel pharmaceutical formulation
US20220056044A1 (en) * 2018-12-14 2022-02-24 Jiangsu Hengrui Medicine Co., Ltd. Tricyclic compounds as sting agonists, and preparation methods and medicinal uses thereof
WO2020132566A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting pyrazole agonists and uses thereof
WO2020132582A1 (en) * 2018-12-21 2020-06-25 Nimbus Titan, Inc. Sting agonists and uses thereof
US12129267B2 (en) 2019-01-07 2024-10-29 Incyte Corporation Heteroaryl amide compounds as sting activators
CN111471056B (zh) * 2019-01-23 2021-07-02 成都先导药物开发股份有限公司 一种大环类免疫调节剂
US20220119379A1 (en) * 2019-01-31 2022-04-21 Hitgen Inc. Immunomodulator
WO2020165600A1 (en) 2019-02-14 2020-08-20 Bicycletx Limited Bicyclic peptide ligand sting conjugates and uses thereof
CN113543851B (zh) 2019-03-07 2025-03-18 捷克共和国有机化学与生物化学研究所 2’3’-环二核苷酸及其前药
KR102808642B1 (ko) 2019-03-07 2025-05-14 인스티튜트 오브 오가닉 케미스트리 앤드 바이오케미스트리 에이에스 씨알 브이.브이.아이. 3'3'-사이클릭 다이뉴클레오티드 및 이의 프로드럭
EP3935065A1 (en) 2019-03-07 2022-01-12 Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator
AU2020240135A1 (en) 2019-03-21 2021-10-14 Lonza Sales Ag Extracellular vesicles for vaccine delivery
WO2020191377A1 (en) 2019-03-21 2020-09-24 Codiak Biosciences, Inc. Extracellular vesicle conjugates and uses thereof
CN113631228B (zh) 2019-03-28 2023-10-13 鲁宾有限公司 作为sting激动剂的大环化合物
TW202104214A (zh) 2019-04-05 2021-02-01 英商葛蘭素史密斯克藍智慧財產發展有限公司 化合物
WO2021000770A1 (zh) * 2019-07-02 2021-01-07 凯复制药有限公司 可增强免疫活性的杂环化合物、其制备方法及其在医药上的应用
WO2021003445A1 (en) 2019-07-03 2021-01-07 Codiak Biosciences, Inc. Extracellular vesicles targeting t cells and uses thereof
US11339159B2 (en) 2019-07-17 2022-05-24 Pfizer Inc. Toll-like receptor agonists
GB201910305D0 (en) * 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
GB201910304D0 (en) 2019-07-18 2019-09-04 Ctxt Pty Ltd Compounds
EP4004002B1 (en) * 2019-07-22 2024-07-10 Lupin Limited Macrocyclic compounds as sting agonists and methods and uses thereof
CN112279835B (zh) * 2019-07-24 2022-07-22 中国医学科学院药物研究所 芳环或芳杂环并咪唑类化合物，其制备方法及制药用途
CN112300227B (zh) * 2019-07-25 2023-11-28 江西济民可信集团有限公司 杂环酰胺类化合物及其制备方法和应用
MX2022001407A (es) 2019-08-02 2022-04-27 Mersana Therapeutics Inc Compuestos derivados y relacionados de bis-[n-((5-carbamoil)-1h be nzo[d]imidazol-2-yl)-pyrazol-5-carboxamida] como agonistas de sting (estimulador de genes de interferón) para el tratamiento de cáncer.
CN112521371B (zh) * 2019-09-19 2022-11-25 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
CN112521394A (zh) * 2019-09-19 2021-03-19 中国药科大学 杂环酰胺类化合物、其可药用的盐及其制备方法和用途
AU2020351729A1 (en) 2019-09-25 2022-04-21 Lonza Sales Ag STING agonist comprising exosomes combined with IL-12 displaying exosomes for treating a tumour
US20230241089A1 (en) 2019-09-25 2023-08-03 Codiak Biosciences, Inc. Sting agonist comprising exosomes for treating neuroimmunological disorders
US20240099973A1 (en) 2019-09-25 2024-03-28 Lonza Sales Ag Extracellular vesicle compositions
WO2021062290A1 (en) 2019-09-25 2021-04-01 Codiak Biosciences, Inc. Methods of producing extracellular vesicles
CN114555602B (zh) * 2019-10-10 2024-02-06 百济神州有限公司 作为sting调节剂的杂环化合物
CN112778336B (zh) * 2019-11-02 2023-05-05 上海凌达生物医药有限公司 一类含氮稠环类sting调节剂类化合物、制备方法和用途
CN112940004B (zh) * 2019-12-11 2022-07-12 中国科学院上海药物研究所 一种杂环化合物及其用途
WO2021119753A1 (en) 2019-12-18 2021-06-24 Ctxt Pty Limited Compounds
CN113087668B (zh) * 2019-12-23 2022-11-04 中国科学院上海药物研究所 一类苯并咪唑二聚体、其制备方法及用途
CN113248475B (zh) * 2020-02-11 2023-03-17 中国科学院上海药物研究所 一类杂环取代的苯并咪唑二聚体或其药学上可接受的盐、组合物及其用途
IL296124A (en) 2020-03-06 2022-11-01 Daiichi Sankyo Co Ltd Antibody-drug conjugate including novel cyclic dinucleotide derivative
US20230114434A1 (en) 2020-03-13 2023-04-13 Codiak Biosciences, Inc. Extracellular vesicles for treating neurological disorders
EP4121450A2 (en) 2020-03-20 2023-01-25 Codiak BioSciences, Inc. Extracellular vesicles for therapy
KR20230004896A (ko) 2020-04-02 2023-01-06 메르사나 테라퓨틱스, 인코포레이티드 스팅 효능제를 포함하는 항체 약물 접합체
KR20220167275A (ko) 2020-04-10 2022-12-20 오노 야꾸힝 고교 가부시키가이샤 암 치료 방법
WO2021237100A1 (en) 2020-05-21 2021-11-25 Codiak Biosciences, Inc. Methods of targeting extracellular vesicles to lung
CA3193264A1 (en) * 2020-09-02 2022-03-10 The Scripps Research Institute Agonists of stimulator of interferon genes sting
TW202227479A (zh) 2020-09-02 2022-07-16 日商第一三共股份有限公司 新穎內－β－Ｎ－乙醯葡萄糖胺苷酶
WO2022066883A1 (en) 2020-09-23 2022-03-31 Codiak Biosciences, Inc. Extracellular vesicles comprising kras antigens and uses thereof
CA3192470A1 (en) 2020-09-23 2022-03-31 Tim SOOS Methods of producing extracellular vesicles
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
WO2022155518A1 (en) 2021-01-15 2022-07-21 Seagen Inc. Immunomodulatory antibody-drug conjugates
CN112920172B (zh) * 2021-02-01 2022-03-22 厦门大学 一种干扰素刺激蛋白靶向化合物、其放射性标记物、及它们的制备方法与应用
KR20220117805A (ko) 2021-02-17 2022-08-24 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
WO2022177307A1 (ko) * 2021-02-17 2022-08-25 한국화학연구원 벤즈이미다졸 유도체를 유효 성분으로 포함하는 인터페론 유전자 자극제 조성물
EP4326769A1 (en) 2021-04-20 2024-02-28 Institut Curie Compositions and methods for use in immunotherapy
WO2022248353A1 (en) 2021-05-24 2022-12-01 Glaxosmithkline Biologicals Sa Adjuvants
WO2022246597A1 (en) * 2021-05-24 2022-12-01 Forever Millets Limited Imidazopyridine derivatives as sting agonists
US20250057967A2 (en) * 2021-06-25 2025-02-20 Bolt Biotherapeutics, Inc. Bis-benzimidazole sting agonist immunoconjugates, and uses thereof
WO2023020994A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020992A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023020993A1 (en) 2021-08-16 2023-02-23 Glaxosmithkline Biologicals Sa Novel methods
WO2023025256A1 (zh) * 2021-08-26 2023-03-02 成都先导药物开发股份有限公司 一种适合作为抗体偶联药物效应分子的sting激动剂
WO2023056468A1 (en) 2021-09-30 2023-04-06 Codiak Biosciences, Inc. Extracellular vesicle comprising cholesterol tagged sting-agonist
EP4169513A1 (en) 2021-10-19 2023-04-26 GlaxoSmithKline Biologicals S.A. Adjuvant composition comprising sting agonists
EP4463450A1 (en) * 2022-01-11 2024-11-20 Bisichem Co., Ltd. Fused heteroaryl hydroxamates as sting agonists
IL314136A (en) * 2022-02-02 2024-09-01 Hoffmann La Roche Imidazole macrocycles for the treatment of autoimmune disease
JP2025506768A (ja) 2022-02-22 2025-03-13 アラリス バイオテック アーゲー ２つ以上のペイロードを含むペプチドリンカー
US20250207169A1 (en) 2022-03-02 2025-06-26 Daiichi Sankyo Company, Limited METHOD FOR PRODUCING Fc-CONTAINING MOLECULE
WO2024003773A1 (en) 2022-07-01 2024-01-04 Pfizer Inc. 2,7-naphthyridine compounds as mastl inhibitors
JP2025525406A (ja) 2022-07-05 2025-08-05 ファイザー・インク ピリド［４，３－ｄ］ピリミジン化合物
AU2023336004A1 (en) 2022-08-29 2025-03-06 Daiichi Sankyo Company, Limited Antibody-drug conjugate including mutant fc region
EP4598901A1 (en) * 2022-10-03 2025-08-13 Thomas Jefferson University Pyrrolidine and imidazolidine based dna polymerase theta inhibitors and use thereof
WO2024074977A1 (en) 2022-10-04 2024-04-11 Pfizer Inc. Substituted 1 h-pyrazolo-pyridine and-pyrimidine compounds
WO2024084364A1 (en) 2022-10-18 2024-04-25 Pfizer Inc. Compounds for the treatment of cancer
WO2024105563A1 (en) 2022-11-16 2024-05-23 Pfizer Inc. Substituted bicyclic pyridone derivatives
WO2024137619A1 (en) 2022-12-20 2024-06-27 Bolt Biotherapeutics, Inc. Anti-claudin, bis-benzimid azole sting agonist immunoconjugates, and uses thereof
WO2024180103A1 (en) 2023-02-27 2024-09-06 BioNTech SE Sting agonists containing benzylic alcohol and benzylic amine functional groups
WO2024182414A1 (en) 2023-02-27 2024-09-06 Biontech Us Inc. Sting agonists containing hydrazide, hydrazine, and hydroxamic acid functional groups
WO2024186626A1 (en) 2023-03-03 2024-09-12 Bolt Biotherapeutics, Inc. Aza-bicyclic sting agonist immunoconjugates, and uses thereof
WO2024209339A1 (en) 2023-04-05 2024-10-10 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
WO2024213979A1 (en) 2023-04-10 2024-10-17 Pfizer Inc. Pyrido[4,3-d]pyrimidine compounds
AR133199A1 (es) * 2023-07-10 2025-09-03 F Hoffmann La Roche Ag Macrociclos bicíclicos para el tratamiento de enfermedades autoinmunitarias
US20250108048A1 (en) * 2023-07-31 2025-04-03 Sutro Biopharma, Inc. Sting agonist compounds and conjugates
KR20250040871A (ko) * 2023-09-15 2025-03-25 삼진제약주식회사 Sting(인터페론 유전자 자극인자) 활성화제로서의 헤테로 고리 유도체 및 이를 포함하는 약학적 조성물
EP4534147A1 (en) 2023-10-05 2025-04-09 Sulis Therapeutics ApS Sting antagonist compounds
WO2025094035A1 (en) 2023-11-01 2025-05-08 Pfizer Inc. Toll-like receptor agonists and conjugates thereof

Family Cites Families (105)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681835A (en) 1994-04-25 1997-10-28 Glaxo Wellcome Inc. Non-steroidal ligands for the estrogen receptor
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9716557D0 (en) 1997-08-06 1997-10-08 Glaxo Group Ltd Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
GB9824310D0 (en) * 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
CA2310896A1 (en) 1999-07-02 2001-01-02 Japan Tobacco Inc. Hcv polymerase suitable for crystal structure analysis and method for using the enzyme
KR100996759B1 (ko) 1999-08-24 2010-11-25 메다렉스, 인코포레이티드 인간 씨티엘에이-4 항체 및 그의 용도
US7605238B2 (en) 1999-08-24 2009-10-20 Medarex, Inc. Human CTLA-4 antibodies and their uses
JP3871503B2 (ja) 1999-08-30 2007-01-24 日本たばこ産業株式会社 免疫性疾患治療剤
JP4210454B2 (ja) 2001-03-27 2009-01-21 日本たばこ産業株式会社 炎症性腸疾患治療剤
CZ20013424A3 (cs) 1999-12-27 2002-02-13 Japan Tobacco Inc. Sloučeniny s fúzovanými kruhy a jejich pouľití jako léčiva
MXPA02011486A (es) 2000-05-19 2004-01-26 Corixa Corp Tratamiento profilactico y terapeutico de enfermedades infecciosas, autoinmunes y alergicas con compuestos a base de mono y disacarido.
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2417806C (en) 2000-08-04 2011-05-10 Corixa Corporation New immunoeffector compounds
US6310224B1 (en) 2001-01-19 2001-10-30 Arco Chemical Technology, L.P. Epoxidation catalyst and process
MY134070A (en) 2001-01-22 2007-11-30 Isis Pharmaceuticals Inc Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase
JP4212278B2 (ja) 2001-03-01 2009-01-21 日本たばこ産業株式会社 移植片拒絶反応抑制剤
IL157940A0 (en) 2001-03-19 2004-03-28 Ono Pharmaceutical Co Drugs containing triazaspiro [5.5] undecane derivatives as the active ingredient
AR035543A1 (es) 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
JP4558314B2 (ja) 2001-07-20 2010-10-06 ベーリンガー インゲルハイム （カナダ） リミテッド ウイルスポリメラーゼインヒビター
US6525028B1 (en) 2002-02-04 2003-02-25 Corixa Corporation Immunoeffector compounds
US6911434B2 (en) 2002-02-04 2005-06-28 Corixa Corporation Prophylactic and therapeutic treatment of infectious and other diseases with immunoeffector compounds
IL164376A0 (en) 2002-04-03 2005-12-18 Applied Research Systems Ox4or binding agents, their preparation and pharmaceutical compositions containing them
US20030215917A1 (en) 2002-04-04 2003-11-20 Mingjun Huang Assay for evaluation of activity of compounds against HCV using a novel detection system in the HCV replicon
DOP2003000641A (es) 2002-05-10 2003-11-15 Pfizer Inhibidores de las arn polimerasa dependiente de arn del virus de las hepatitis c y composiciones y tratamiento que los usan
DE60317677T2 (de) 2002-06-13 2008-10-30 Crucell Holland B.V. Ox40 (=cd134) rezeptor agonisten und therapeutische verwendung
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
PL376454A1 (en) 2002-10-24 2005-12-27 Glaxo Group Limited 1-acyl-pyrrolidine derivatives for the treatment of viral infections
UA79834C2 (en) 2002-11-01 2007-07-25 Viropharma Inc Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
ATE410426T1 (de) 2002-12-13 2008-10-15 Smithkline Beecham Corp Heterocyclische verbindungen alsccr5-antagonisten
WO2004054581A2 (en) 2002-12-13 2004-07-01 Smithkline Beecham Corporation Cyclohexyl compounds as ccr5 antagonists
ES2309400T3 (es) 2002-12-13 2008-12-16 Smithkline Beecham Corporation Compuestos de pirrolidina y azetidina como antagonistas de ccr5.
ATE384724T1 (de) 2002-12-13 2008-02-15 Smithkline Beecham Corp Cyclopropylverbindungen als ccr5 antagonisten
AU2003300902A1 (en) 2002-12-13 2004-07-09 Smithkline Beecham Corporation Piperidine derivatives as CCR5 antagonists
EP1581530A1 (en) 2002-12-13 2005-10-05 Smithkline Beecham Corporation Indane compounds as ccr5 antagonists
EP1576014B1 (en) 2002-12-23 2011-06-29 Wyeth LLC Antibodies against pd-1 and uses thereof
US7960522B2 (en) 2003-01-06 2011-06-14 Corixa Corporation Certain aminoalkyl glucosaminide phosphate compounds and their use
US7098231B2 (en) 2003-01-22 2006-08-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US7223785B2 (en) 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
ES2729974T3 (es) 2003-01-23 2019-11-07 Ono Pharmaceutical Co Anticuerpo específico de PD-1 y CD3 humanas
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
JP2007501189A (ja) 2003-08-01 2007-01-25 ジェネラブス テクノロジーズ，インコーポレイテッド フラビウイルス科に対する二環式イミダゾール誘導体
WO2005014543A1 (ja) 2003-08-06 2005-02-17 Japan Tobacco Inc. 縮合環化合物及びそのｈｃｖポリメラーゼ阻害剤としての利用
WO2005070420A1 (en) 2004-01-14 2005-08-04 Boehringer Ingelheim Pharmaceuticals, Inc. 1h-benzimidazol-2-yl-benzamide derivatives and related compounds as itk inhibitors (interleukin-2-inducible t cell kinase) for the treatment of inflammation, immunological and allergic disorders
CA2553433A1 (en) 2004-01-23 2005-08-11 Amgen Inc. Quinoline quinazoline pyridine and pyrimidine compounds and their use in the treatment of inflammation angiogenesis and cancer
RS52931B (en) 2004-02-20 2014-02-28 Boehringer Ingelheim International Gmbh VIRAL POLYMERASE INHIBITORS
US7709458B2 (en) 2004-03-15 2010-05-04 David K. R. Karaolis Method for inhibiting cancer cell proliferation or increasing cancer cell apoptosis
KR20070011501A (ko) 2004-04-28 2007-01-24 애로우 쎄라퓨틱스 리미티드 항바이러스제로서 유용한 모르폴리닐아닐리노퀴나졸린유도체
TW200600492A (en) 2004-05-18 2006-01-01 Achillion Pharmaceuticals Inc Substituted aryl acylthioureas and related compounds; inhibitors of viral replication
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
AP2313A (en) 2004-08-18 2011-10-31 Pfizer Inhibitors of hepatitis C virus RNA-dependent RNA ploymerase, and compositions and treatments using the same.
GB0423673D0 (en) 2004-10-25 2004-11-24 Glaxo Group Ltd Compounds
US20070060589A1 (en) * 2004-12-21 2007-03-15 Purandare Ashok V Inhibitors of protein arginine methyl transferases
WO2006117306A1 (en) 2005-05-04 2006-11-09 F. Hoffmann-La Roche Ag Heterocyclic antiviral compounds
CA2607617A1 (en) 2005-05-09 2006-11-16 Achillion Pharmaceuticals, Inc. Thiazole compounds and methods of use
CA3151350A1 (en) 2005-05-09 2006-11-16 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
MY153424A (en) 2005-05-10 2015-02-13 Incyte Corp Modulators of indoleamine 2,3-dioxygenase and methods of using the same
BRPI0613361A2 (pt) 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
EP1782826A1 (en) 2005-11-08 2007-05-09 GBF Gesellschaft für Biotechnologische Forschung mbH PQS and c-diGMP and its conjugates as adjuvants and their uses in pharmaceutical compositions
US8017612B2 (en) 2006-04-18 2011-09-13 Japan Tobacco Inc. Piperazine compound and use thereof as a HCV polymerase inhibitor
US8329159B2 (en) 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2068925A4 (en) 2007-05-07 2011-08-31 Medimmune Llc ANTI-ICOS ANTIBODIES AND THEIR USE FOR THE TREATMENT OF CANCER, TRANSPLANTATIONS AND AUTOIMMUNE DISEASES
KR20100054780A (ko) 2007-06-18 2010-05-25 엔.브이.오가논 사람 프로그램된 사멸 수용체 ｐｄ-1에 대한 항체
PT2242771E (pt) 2007-12-14 2013-08-29 Bristol Myers Squibb Co Moléculas de ligação ao recetor humano ox40
CA2713658C (en) 2008-02-01 2016-07-05 Takeda Pharmaceutical Company Limited Oxim derivatives as hsp90 inhibitors
WO2009114335A2 (en) 2008-03-12 2009-09-17 Merck & Co., Inc. Pd-1 binding proteins
CA2724430A1 (en) * 2008-05-19 2009-11-26 Schering Corporation Heterocyclic compounds as factor ixa inhibitors
CN104740610A (zh) 2008-08-25 2015-07-01 安普利穆尼股份有限公司 Pd-1拮抗剂及其使用方法
ES2982109T3 (es) 2008-09-26 2024-10-14 Dana Farber Cancer Inst Inc Anticuerpos anti PD-1, PD-L1 y PD-L2 humanos y usos de los mismos
JP5933975B2 (ja) 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
KR20230070055A (ko) 2008-12-09 2023-05-19 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
CN102427726B (zh) 2009-03-27 2014-10-08 普雷西迪奥制药公司 丙型肝炎的稠环抑制剂
EP2504028A4 (en) 2009-11-24 2014-04-09 Amplimmune Inc SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2
US8779108B2 (en) 2009-11-24 2014-07-15 Medimmune, Limited Targeted binding agents against B7-H1
US8362020B2 (en) 2009-12-30 2013-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2011091446A1 (en) * 2010-01-22 2011-07-28 Glaxosmithkline Llc Chemical compounds
CA2794153C (en) * 2010-03-25 2018-01-02 Glaxosmithkline Llc Substituted indoline derivatives as perk inhibitors
UY33288A (es) * 2010-03-25 2011-10-31 Glaxosmithkline Llc Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico
US20110280877A1 (en) 2010-05-11 2011-11-17 Koji Tamada Inhibition of B7-H1/CD80 interaction and uses thereof
CA3084173A1 (en) 2010-05-17 2011-11-24 Rhizen Pharmaceuticals Sa Novel 3,5-disubstitued-3h-imidazo[4,5-b]pyridine and 3,5- disubstitued_-3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of protein kinases
CN101898945B (zh) 2010-07-27 2013-05-08 大连理工大学 盐析萃取发酵液中丙酮和丁醇的方法
JP5984810B2 (ja) 2010-08-23 2016-09-06 ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム 抗ｏｘ４０抗体およびそれを使用する方法
EP2651926A4 (en) 2010-12-15 2014-07-09 Abbvie Inc ANTI-VIRAL COMPOUNDS
SG193428A1 (en) 2011-03-31 2013-10-30 Inst Nat Sante Rech Med Antibodies directed against icos and uses thereof
AU2012290121B2 (en) 2011-08-01 2015-11-26 Genentech, Inc. Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors
RU2562874C1 (ru) 2011-08-23 2015-09-10 Борд Оф Риджентс, Дзе Юниверсити Оф Техас Систем Антитела против ох40 и способы их применения
AU2013256468A1 (en) 2012-04-30 2014-12-04 Glen N. Barber Modulating immune responses
BR122022015975B1 (pt) 2012-05-15 2024-01-02 Bristol-Myers Squibb Company Anticorpos monoclonais, kit para o tratamento de um indivíduo afligido com um câncer, processo para medir pd-l1 membranoso em células tumorais isoladas e uso do anticorpo ou uma porção que se liga ao antígeno do mesmo
CN104507538B (zh) 2012-06-08 2018-04-06 艾杜罗生物科技公司 癌症免疫疗法的组合物和方法
EA029718B1 (ru) * 2012-06-27 2018-05-31 4-Эс-Си Дискавери Гмбх Бифтордиоксалан-аминобензимидазольные ингибиторы киназы для лечения рака, аутоиммунного воспаления и нарушений цнс
ES2684552T3 (es) 2012-09-03 2018-10-03 Inserm - Institut National De La Santé Et De La Recherche Médicale Anticuerpos dirigidos contra ICOS para tratar la enfermedad de injerto contra hospedador
JP6461800B2 (ja) 2012-10-04 2019-01-30 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ヒトモノクローナル抗ｐｄ−ｌ１抗体および使用方法
US9695212B2 (en) 2012-12-13 2017-07-04 Aduro Biotech, Inc. Compositions comprising cyclic purine dinucleotides having defined stereochemistries and methods for their preparation and use
US9549944B2 (en) 2013-05-18 2017-01-24 Aduro Biotech, Inc. Compositions and methods for inhibiting “stimulator of interferon gene”—dependent signalling
ES2754269T3 (es) 2013-05-18 2020-04-16 Aduro Biotech Inc Composiciones y métodos de activación de la señalización dependiente del "estimulador de los genes de interferón
JP2016538344A (ja) 2013-11-19 2016-12-08 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 癌処置としてのｓｔｉｎｇアゴニストの使用
US10227638B2 (en) 2014-06-02 2019-03-12 Base4 Innovation Ltd. Nucleotide polymorphism detection method
EP3152217B1 (en) * 2014-06-04 2018-08-01 GlaxoSmithKline Intellectual Property Development Limited Cyclic di-nucleotides as modulators of sting
MX384364B (es) 2014-07-11 2025-03-14 Ventana Med Syst Inc Anticuerpos anti-pd-l1 y sus usos de diagnóstico.
MA41414A (fr) 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
JP6944924B2 (ja) 2015-03-23 2021-10-06 ジョンス セラピューティクス， インコーポレイテッド Ｉｃｏｓに対する抗体
SG10202010609QA (en) 2015-08-13 2020-11-27 Merck Sharp & Dohme Cyclic di-nucleotide compounds as sting agonists
EP3322713B1 (en) 2015-12-03 2021-01-20 GlaxoSmithKline Intellectual Property Development Limited Cyclic purine dinucleotides as modulators of sting
PE20181919A1 (es) 2016-04-07 2018-12-11 Glaxosmithkline Ip Dev Ltd Amidas heterociclicas utiles como moduladores de proteinas
WO2017175156A1 (en) 2016-04-07 2017-10-12 Glaxosmithkline Intellectual Property Development Limited Heterocyclic amides useful as protein modulators

Also Published As

Publication number Publication date
NZ750114A (en) 2025-05-30
LT3440076T (lt) 2022-09-26
KR20180124149A (ko) 2018-11-20
EP4032885A1 (en) 2022-07-27
CL2018002850A1 (es) 2018-12-14
IL285702A (en) 2021-09-30
AU2018229497A1 (en) 2018-10-04
BR112018070655A2 (pt) 2019-02-05
JP2019510796A (ja) 2019-04-18
SG10201900629VA (en) 2019-02-27
CR20200044A (es) 2020-03-11
WO2017175147A1 (en) 2017-10-12
PH12018502151A1 (en) 2019-07-08
DOP2018000217A (es) 2018-10-31
IL285702B (en) 2022-09-01
CL2018003290A1 (es) 2019-02-01
PH12018502151B1 (en) 2022-01-12
CA3019630A1 (en) 2017-10-12
NZ745957A (en) 2020-07-31
JP2020100646A (ja) 2020-07-02
CN109071514A (zh) 2018-12-21
KR102527786B1 (ko) 2023-04-28
BR122018070836A8 (pt) 2022-07-19
PE20181920A1 (es) 2018-12-11
MY189100A (en) 2022-01-25
BR122018070838A8 (pt) 2022-07-19
JP2021105013A (ja) 2021-07-26
MX379169B (es) 2025-03-10
PH12018502202A1 (en) 2020-06-22
CO2018010727A2 (es) 2018-10-22
TW201738235A (zh) 2017-11-01
PE20181884A1 (es) 2018-12-07
JP6861307B2 (ja) 2021-04-21
EP3440076A1 (en) 2019-02-13
IL261482B (en) 2021-09-30
SG10201900628RA (en) 2019-02-27
AU2017247798B2 (en) 2019-10-31
BR122018070836A2 (pt) 2019-09-10
AU2018229497C1 (en) 2020-09-03
MX2020009948A (es) 2021-10-26
MX2020009947A (es) 2021-10-26
SG11201808621TA (en) 2018-10-30
AU2017247798C1 (en) 2020-08-27
US11365190B2 (en) 2022-06-21
JOP20170083B1 (ar) 2022-03-14
JP7119158B2 (ja) 2022-08-16
HRP20220936T1 (hr) 2022-10-28
TW201920161A (zh) 2019-06-01
PL3440076T3 (pl) 2022-09-05
US10981901B1 (en) 2021-04-20
RS63462B1 (sr) 2022-08-31
IL261657A (en) 2018-10-31
IL295649B1 (en) 2025-08-01
JP6746712B2 (ja) 2020-08-26
MX387354B (es) 2025-03-18
CL2018003291A1 (es) 2019-02-01
SMT202200339T1 (it) 2022-09-14
TWI868471B (zh) 2025-01-01
DOP2020000018A (es) 2020-03-15
AU2018229498B2 (en) 2019-06-27
DK3440076T3 (da) 2022-07-11
AU2020200692B2 (en) 2020-08-27
AU2017247798A1 (en) 2018-09-27
AU2018229498A1 (en) 2018-10-04
CR20200045A (es) 2020-03-11
SI3440076T1 (sl) 2022-09-30
TW202246285A (zh) 2022-12-01
UY37195A (es) 2017-10-31
IL261657B (en) 2021-09-30
US20180105514A1 (en) 2018-04-19
US10189820B2 (en) 2019-01-29
CN113549110A (zh) 2021-10-26
US11970480B2 (en) 2024-04-30
US20230071675A1 (en) 2023-03-09
JP2022166060A (ja) 2022-11-01
CN113549110B (zh) 2024-08-16
HUE058932T2 (hu) 2022-09-28
BR122018070838A2 (pt) 2019-09-10
MX2018012333A (es) 2019-03-07
CN109071514B (zh) 2021-07-06
AU2018229498C1 (en) 2020-09-03
MX387353B (es) 2025-03-18
KR20180132806A (ko) 2018-12-12
TWI776806B (zh) 2022-09-11
PH12018502179A1 (en) 2020-06-15
TWI777014B (zh) 2022-09-11
UA123407C2 (uk) 2021-03-31
KR102527784B1 (ko) 2023-04-28
IL261482A (en) 2018-10-31
IL295649A (en) 2022-10-01
JP7466596B2 (ja) 2024-04-12
CN109608443B (zh) 2021-09-07
AU2020200692C1 (en) 2021-03-04
PT3440076T (pt) 2022-07-29
AU2018229497B2 (en) 2019-06-27
EP3440076B1 (en) 2022-06-01
CN109608443A (zh) 2019-04-12
DOP2020000019A (es) 2020-03-15
US20210139473A1 (en) 2021-05-13
AU2020200692A1 (en) 2020-02-20
ES2921855T3 (es) 2022-09-01

Similar Documents

Publication Publication Date Title
PE20181919A1 (es) Amidas heterociclicas utiles como moduladores de proteinas
MX381313B (es) Derivados de benzimidazol como moduladores de ror-gamma
PE20200696A1 (es) Moduladores de moleculas pequenas de sting humana
MX2020000690A (es) Compuestos heterociclicos como antagonistas de adenosina.
MX376062B (es) Agonistas del receptor muscarinico.
MX375639B (es) Derivados de heterociclilos sustituidos como inhibidores de cdk
PE20170695A1 (es) Compuestos de indol carboxamida utiles como inhibidores de cinasas
EA201390821A1 (ru) Антагонисты рецепторов лизофосфатидной кислоты и их применение
PE20161427A1 (es) Inhibidores heteroarilo de syk
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
MX379110B (es) Derivados de azaspiro como antagonistas de trpm8.
CL2014002732A1 (es) Compuestos derivados de imidazolil-pirimidinas sustituidas con amino-indolilo, inhibidores de la proteina quinasa syk; compuestos intermediarios; formulaciones farmaceuticas que los contienen; uso en el tratamiento de enfermedades tales como asma, epoc, rinitis alergica, entre otras.
MX2016008131A (es) Compuestos heterociclos biciclicos y sus usos en terapia.
MX2019006893A (es) Inhibidores heterociclicos de mct4.
MX376700B (es) Compuestos heterociclicos fusionados como moduladores s1p.
PE20170914A1 (es) 1-[2-(aminometil)bencil]-2-tioxo-1,2,3,5-tetrahidro-4h-pirrolo[3,2-d]pirimidin-4-onas como inhibidores de mieloperoxidasa
EP3444254A4 (en) HETEROCYCLICALLY SUBSTITUTED PYRIDINOPYRIMIDINONE DERIVATIVE AS CDK INHIBITOR AND USE THEREOF
CY1125333T1 (el) Μεθοδος παρασκευης μιας κρυσταλλικης μορφης της μηλεϊνικης 1-((2r, 4r)-2- (1h-benzo[d] ιμιδαζολ-2- υλο)-1-μεθυλο-πιπεριδιν-4-υλο)-3-(4- κυανοφαινυλ)ουριας· μια κρυσταλλικη μορφη συμπλοκου 1-((2r, 4r)-2- (1h-benzo[d] ιμιδαζολ-2- υλο)-1-μεθυλοπιπεριδιν-4-υλο)-3-(4-κυανοφαινυλ) ουριας ιμιδαζολης (1:1)
AU2020288559A8 (en) Pyrazole and imidazole derivatives, compositions and methods as orexin antagonists
EA202090414A1 (ru) Соединения и их применение
PE20181337A1 (es) Sales de un inhibidor de pim quinasa
UY31682A1 (es) Compuestos derivados de azetetidinas, su preparacion y su aplicacion en terapeutica
EA201692289A1 (ru) Замещенные [1,2,4]триазольные и имидазольные соединения в качестве фунгицидов
EA201692402A1 (ru) Лекарственные формы для местного применения и их использование
EA201600436A1 (ru) Кристаллическая солевая форма (s)-(2-(6-хлор-7-метил-1h-бензо[d]имидазол-2-ил)-2-метилпирролидин-1-ил)(5-метокси-2-(2h-1,2,3-триазол-2-ил)фенил)метанона и ее применение в качестве антагонистов орексинового рецептора